|
Post by ezrasfund on Jan 26, 2020 20:56:22 GMT -5
You folks are talking like traders. Yes, all of those factors matter in the short term. In the end it is the Rx count that matters and cash flow. Right now Rx is on a steady up trend. If it continues steep enough and long enough to get us to positive cash flow before bankruptcy, that's the first step. (OK throw in some cash from the UTHR deal and others.) Then the question becomes how much of the insulin market Afrezza can capture. Until 20x earnings is a big number MNKD's value will be mostly speculative.
A better way to envision this as the bottom is to look at the reverse split from the other side. Share price peaked around $11 and is now $1.75/5 = $0.35 Now, that still feels like a bottom and not that far from the real bottom of about $0.16.
|
|
|
Post by Omega on Jan 26, 2020 21:00:10 GMT -5
It was 33,000 no to long ago. Golfeveryday knows. 33,000 what? People on ST that clicked to watch/follow MNKD MNKD ST watchers 2/01/2018: 30,154 (2 years ago) 2/01/2019: 33,425 (1 year ago) 1/26/2020: 35,181 (Today)
|
|
|
Post by brotherm1 on Jan 26, 2020 21:14:56 GMT -5
🤔perhaps the “watching” word used by Stock Twits would be more accurate if it was somehow like “have watched” and within a certain time period. I wonder how many of the 35,000 “watching” still check in.
|
|
|
Post by sportsrancho on Jan 26, 2020 21:42:31 GMT -5
It was 33,000 no to long ago. Golfeveryday knows. 33,000 what? Watchers on ST. 35,181 right now.
|
|
|
Post by mytakeonit on Jan 26, 2020 21:46:54 GMT -5
So all of you who delve in the past and not see the future? After the CC let's see if you see a different picture. The 3rd quarter CC spelled it all out for me and a few others. In any case, I'm happy and have the patience to wait a few more months. Then, I'll wait a few more years as I've posted. For now, let's see what next week brings. But, that's mytakeonit
|
|
|
Post by prcgorman2 on Jan 26, 2020 21:53:58 GMT -5
I assume Dr. Castagna is pursuing strategic investment on candidate molecule(s) in the pipeline to acquire the bridge capital between what is available from Afrezza, MidCap, and UTHR and what is required to get to CFBE and profitability.
|
|
|
Post by brotherm1 on Jan 26, 2020 22:02:13 GMT -5
Did he not basically say they need to first get the molecules in the pipeline into clinical trials first before anyone would even be interested?
|
|
|
Post by ilovekauai on Jan 26, 2020 22:58:23 GMT -5
I'm adding tomorrow morning. Here I go again. Hoping it's the right decision. Why does this always have to be so complicated? I promise to remain chill and deal with it. Cheers.
|
|
|
Post by mytakeonit on Jan 26, 2020 23:24:50 GMT -5
If you are setting a buy price ... I hope you can get it. It flew past my buy order for Friday, so I bought more SENS instead.
But, that's mytakeonit
|
|
|
Post by prcgorman2 on Jan 27, 2020 6:19:06 GMT -5
Did he not basically say they need to first get the molecules in the pipeline into clinical trials first before anyone would even be interested? I assume that is what most potential partners would want as a start. I do not assume that is the case for any possible partnership. e.g., RLS.
|
|
|
Post by brotherm1 on Jan 27, 2020 6:22:25 GMT -5
Did he not basically say they need to first get the molecules in the pipeline into clinical trials first before anyone would even be interested? . I don’t know if in November at Piper Jaffray he was talking about all of the molecules - outside of PAH - or not. He also talks about maybe a partner to get to phase one for them and maybe not. The topic starts a little over 20 minutes into the interview. As it progresses he starts the fast talk and then to the point where he’s mumbling. I listened to it several times and still don’t have it down. It would be nice if it was in writing. The webcast will probably expire soon as did the prior in with Cantor in October.
|
|
|
Post by prcgorman2 on Jan 27, 2020 10:25:19 GMT -5
Perhaps Tony Hooper was added to the Board of Directors to help provide seasoned veteran stewardship in the area of business development.
|
|
|
Post by ktim on Jan 27, 2020 18:30:10 GMT -5
So all of you who delve in the past and not see the future? After the CC let's see if you see a different picture. The 3rd quarter CC spelled it all out for me and a few others. In any case, I'm happy and have the patience to wait a few more months. Then, I'll wait a few more years as I've posted. For now, let's see what next week brings. But, that's mytakeonit CCs are always transformative events in my life. I'm sure this one will be something of an epiphany. Terribly exciting... I can hardly wait. I've got a countdown clock ticking down the minutes. (had to use 2 winkies for that)
|
|
|
Post by ktim on Jan 27, 2020 18:38:01 GMT -5
Did he not basically say they need to first get the molecules in the pipeline into clinical trials first before anyone would even be interested? I assume that is what most potential partners would want as a start. I do not assume that is the case for any possible partnership. e.g., RLS. Prior to Mike there were many deals like RLS that had little if any payment and apparently left progress open ended, so that these "partners" hold onto the exclusive rights despite slow or non existent progress. When Mike talked about not making deals until Phase 1 was complete I interpreted that as indicating a break from those past practices. Deals like RLS, where it appears they have been sitting on exclusivity in cannabinoid space for years at a cost of only $1M seems a pretty sweet deal for RLS and not so much for MNKD. I would hope Mike doesn't do that sort of deal again... and I'm not saying RLS isn't real, for all I know they might register a Phase 1 tomorrow, but it's been too long and they paid too little for open ended exclusivity.
|
|
|
Post by falconquest on Jan 27, 2020 18:57:52 GMT -5
Perhaps Tony Hooper was added to the Board of Directors to help provide seasoned veteran stewardship in the area of business development. Thought that is why we hired Castagna! (I get your point though)
|
|